|
gptkbp:instance_of
|
gptkb:superhero
|
|
gptkbp:activities
|
beta-2 adrenergic agonist
|
|
gptkbp:appointed_by
|
inhalation
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1998
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:Foradil
gptkb:Perforomist
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
hypersensitivity to formoterol
severe asthma exacerbation
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dissolved
|
soluble in water
soluble in ethanol
soluble in methanol
|
|
gptkbp:duration
|
12 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
metered-dose inhaler
nebulizer solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
formoterol fumarate
|
|
gptkbp:ingredients
|
gptkb:formoterol
fumaric acid
C22 H27 N3 O5 S
|
|
gptkbp:interacts_with
|
MAO inhibitors
beta-blockers
tricyclic antidepressants
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
R03 A C13
|
|
gptkbp:is_used_for
|
gptkb:asthma
chronic obstructive pulmonary disease
|
|
gptkbp:level
|
9.5
|
|
gptkbp:lifespan
|
10 hours
|
|
gptkbp:manager
|
dry powder inhaler
inhalation aerosol
|
|
gptkbp:marketed_as
|
gptkb:Breztri_Aerosphere
gptkb:Foradil_Aerolizer
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
headache
nervousness
palpitations
muscle cramps
tremor
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:type_of
|
345-33-3
|
|
gptkbp:bfsParent
|
gptkb:Breztri_Aerosphere
gptkb:Trixeo_Aerosphere
|
|
gptkbp:bfsLayer
|
4
|